EII Stock Overview
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥37.59 |
| 52 Week High | JP¥73.20 |
| 52 Week Low | JP¥35.04 |
| Beta | -0.049 |
| 1 Month Change | -2.19% |
| 3 Month Change | -13.05% |
| 1 Year Change | -27.38% |
| 3 Year Change | -32.27% |
| 5 Year Change | -26.52% |
| Change since IPO | 197.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| EII | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.0% | -3.1% | -2.0% |
| 1Y | -27.4% | -31.9% | -0.3% |
Return vs Industry: EII exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: EII underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| EII volatility | |
|---|---|
| EII Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EII has not had significant price volatility in the past 3 months.
Volatility Over Time: EII's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,076 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| EII fundamental statistics | |
|---|---|
| Market cap | €10.59b |
| Earnings (TTM) | €275.40m |
| Revenue (TTM) | €4.54b |
38.5x
P/E Ratio2.3x
P/S RatioIs EII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EII income statement (TTM) | |
|---|---|
| Revenue | JP¥749.46b |
| Cost of Revenue | JP¥157.79b |
| Gross Profit | JP¥591.67b |
| Other Expenses | JP¥546.25b |
| Earnings | JP¥45.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 158.37 |
| Gross Margin | 78.95% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 19.7% |
How did EII perform over the long term?
See historical performance and comparison